Doosan Corp.’s $100 million investment into Auburn’s Si02 Materials Science creates a strategic partnership to accelerate market development in Asia.
Doosan Corp. is one of South Korea’s largest diversified conglomerates, and it now has an exclusive partnership to sell, market and distribute Si02’s vials, syringes and blood collection tubes in Asia/Oceania. The partnership will eventually extend to the joint development of new technologies.
“The Asia and Oceania region represents a significant market opportunity for vials and syringes specifically designed for biologic drugs and vaccines,” said Lawrence Ganti, president of Si02. “South Korea has become a world leader in biological drug manufacturing, so it makes sense to establish a strong presence with a respected partner in the market.”
Si02 used its technology for safely packaging COVID-19 vaccine doses around the world and has expanded its manufacturing footprint in Auburn 12-fold over the past 18 months.